Inicio・Lista de Acciones・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Abierto

SectorSanidad

3.34 0.91

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

3.2800000000000002

Máximo

3.43

Métricas clave
By Trading Economics
Ingresos	-2.4M -21M
Ventas	-8.8M 1.4M
P/B Media del Sector	22.5 57.366
BPA	-0.09
Margen de beneficios	-1,457.405
Empleados	69
EBITDA	-2.4M -20M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+285.54% upside

Dividendos
By Acuity
Próximas Ganancias	5 nov 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	27M 717M
Apertura anterior	2.43
Cierre anterior	3.34

Noticias sobre sentimiento de mercado

By Acuity

50%

160 / 340 Clasificación en Healthcare

CytomX Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

25 ago 2026, 19:56 UTC

CytomX Therapeutics is trading higher amid positive market conditions and lower crude oil prices, which have decreased treasury yields and boosted investor sentiment.

24 ago 2026, 19:26 UTC

CytomX Therapeutics is trading higher, reflecting gains since Friday's close. Earlier, shares peaked with a gain before pulling back to a modest advance.

21 ago 2026, 19:46 UTC

CytomX Therapeutics Inc. is gaining during Friday's session, despite earlier volatility. No specific company news was identified to explain today's price movement.

20 ago 2026, 21:01 UTC

CytomX Therapeutics Inc shares are higher in after-market hours, reflecting unusual trading activity. The stock is positioned around the midpoint of its one-month range.

19 ago 2026, 20:02 UTC

CytomX Therapeutics is trading higher during Wednesday's session, continuing a strong upward move since Tuesday's close amid notable volatility.

14 ago 2026, 19:36 UTC

Social Media

CytomX Therapeutics is higher as social media highlights its undervaluation, with a suggested price target of $6-7 ahead of year-end data releases.

13 ago 2026, 22:01 UTC

CytomX Therapeutics shares are higher in after-market trading, supported by broader market strength and a record closing high for the S&P 500.

12 ago 2026, 19:46 UTC

CytomX Therapeutics Inc shares are higher today, continuing an upward trend since Tuesday's close, supported by positive sentiment from the recent inflation report.

11 ago 2026, 23:21 UTC

CytomX Therapeutics Inc. shares are higher in after-market trading, reaching 1.45% above Tuesday's close amid strong performance relative to its moving average.

10 ago 2026, 23:31 UTC

CytomX Therapeutics Inc shares are lower in after-market hours after earlier volatility. Broader market sentiment remains cautious amid geopolitical tensions in the Strait of Hormuz.

7 ago 2026, 19:16 UTC

Social Media

News

CytomX Therapeutics expands collaboration with Regeneron on immunotherapies and updates on Varseta-M program, boosting sentiment amid a rising Biotechnology sector.

6 ago 2026, 22:02 UTC

Social Media

News

CytomX Therapeutics shares declined in after-market hours following a significant revenue miss of $1.418 million against expectations of $12.308 million.

31 jul 2026, 20:06 UTC

CytomX Therapeutics Inc shares declined sharply during Friday's session, reversing earlier gains and trading well below the 20-day moving average. No specific news was identified.

29 jul 2026, 19:47 UTC

CytomX Therapeutics shares are lower as traders await the Federal Reserve's interest rate decision, contributing to mixed performance across major U.S. indices.

28 jul 2026, 17:46 UTC

CytomX Therapeutics shares are lower today, reflecting a broader cautious tone across Asian markets. The stock remains near its one-month low.

27 jul 2026, 23:26 UTC

CytomX Therapeutics shares are higher in after-market hours, though no specific news was identified. Broader positive sentiment in European indices may be influencing investors.

21 jul 2026, 19:56 UTC

CytomX Therapeutics Inc shares are lower today, continuing a downward trend. The stock remains significantly below its 20-day moving average.

Comparación entre iguales

Cambio de precio

CytomX Therapeutics Inc previsión

Precio Objetivo

By TipRanks

285.54% repunte

Estimación a 12 Meses

Media 12.8 USD 285.54%

Máximo 16 USD

Mínimo 11 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CytomX Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para CytomX Therapeutics Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

160 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.